Future directions in gynecologic cancer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cisplatin is one of the most commonly used chemotherapeutic agents to treat gynecologic cancers. However, many patients treated with platinum therapy experience significant toxicities, including neurotoxicity, ototoxicity, and/or nephrotoxicity. Clinical trials have documented the role of amifostine as a cytoprotectant against cisplatin-induced toxicities in patients with advanced ovarian cancer. In these trials, the incidence and severity of many dose-limiting toxicities was reduced significantly by the concomitant administration of amifostine. The management of advanced ovarian, cervical, and endometrial cancers provides many opportunities for future applications of amifostine. Several studies that are being initiated in the United States involve maintaining platinum dose intensity, reducing toxicities, and developing chemotherapeutic combinations that would otherwise have to be avoided without the use of a cytoprotective agent such as amifostine.

Original languageEnglish (US)
Pages (from-to)125-128
Number of pages4
JournalSeminars in Oncology
Volume26
Issue number2 SUPPL. 7
StatePublished - 1999

Fingerprint

Amifostine
Platinum
Ovarian Neoplasms
Cisplatin
Neoplasms
Endometrial Neoplasms
Uterine Cervical Neoplasms
Clinical Trials
Direction compound
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Future directions in gynecologic cancer. / Alberts, David S.

In: Seminars in Oncology, Vol. 26, No. 2 SUPPL. 7, 1999, p. 125-128.

Research output: Contribution to journalArticle

Alberts, DS 1999, 'Future directions in gynecologic cancer', Seminars in Oncology, vol. 26, no. 2 SUPPL. 7, pp. 125-128.
Alberts, David S. / Future directions in gynecologic cancer. In: Seminars in Oncology. 1999 ; Vol. 26, No. 2 SUPPL. 7. pp. 125-128.
@article{0b90565aa393478e9b04f5f8fc1c64bb,
title = "Future directions in gynecologic cancer",
abstract = "Cisplatin is one of the most commonly used chemotherapeutic agents to treat gynecologic cancers. However, many patients treated with platinum therapy experience significant toxicities, including neurotoxicity, ototoxicity, and/or nephrotoxicity. Clinical trials have documented the role of amifostine as a cytoprotectant against cisplatin-induced toxicities in patients with advanced ovarian cancer. In these trials, the incidence and severity of many dose-limiting toxicities was reduced significantly by the concomitant administration of amifostine. The management of advanced ovarian, cervical, and endometrial cancers provides many opportunities for future applications of amifostine. Several studies that are being initiated in the United States involve maintaining platinum dose intensity, reducing toxicities, and developing chemotherapeutic combinations that would otherwise have to be avoided without the use of a cytoprotective agent such as amifostine.",
author = "Alberts, {David S}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "125--128",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Future directions in gynecologic cancer

AU - Alberts, David S

PY - 1999

Y1 - 1999

N2 - Cisplatin is one of the most commonly used chemotherapeutic agents to treat gynecologic cancers. However, many patients treated with platinum therapy experience significant toxicities, including neurotoxicity, ototoxicity, and/or nephrotoxicity. Clinical trials have documented the role of amifostine as a cytoprotectant against cisplatin-induced toxicities in patients with advanced ovarian cancer. In these trials, the incidence and severity of many dose-limiting toxicities was reduced significantly by the concomitant administration of amifostine. The management of advanced ovarian, cervical, and endometrial cancers provides many opportunities for future applications of amifostine. Several studies that are being initiated in the United States involve maintaining platinum dose intensity, reducing toxicities, and developing chemotherapeutic combinations that would otherwise have to be avoided without the use of a cytoprotective agent such as amifostine.

AB - Cisplatin is one of the most commonly used chemotherapeutic agents to treat gynecologic cancers. However, many patients treated with platinum therapy experience significant toxicities, including neurotoxicity, ototoxicity, and/or nephrotoxicity. Clinical trials have documented the role of amifostine as a cytoprotectant against cisplatin-induced toxicities in patients with advanced ovarian cancer. In these trials, the incidence and severity of many dose-limiting toxicities was reduced significantly by the concomitant administration of amifostine. The management of advanced ovarian, cervical, and endometrial cancers provides many opportunities for future applications of amifostine. Several studies that are being initiated in the United States involve maintaining platinum dose intensity, reducing toxicities, and developing chemotherapeutic combinations that would otherwise have to be avoided without the use of a cytoprotective agent such as amifostine.

UR - http://www.scopus.com/inward/record.url?scp=0033035398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033035398&partnerID=8YFLogxK

M3 - Article

C2 - 10348271

AN - SCOPUS:0033035398

VL - 26

SP - 125

EP - 128

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -